Human Genome Safe Harbor Sites: A Comprehensive Review of Criteria, Discovery, Features, and Applications
Authors:
- Amer AhmedAAAmer Ahmed
- Daria Di MolfettaDMDaria Di Molfetta
- Giorgia Natalia IaconisiGIGiorgia Natalia Iaconisi
- Antonello CaponioACAntonello Caponio
- Ansu SinghASAnsu Singh
- Aasia BibiABAasia Bibi
- Vincenza DolceVDVincenza Dolce
- Luigi PalmieriLPLuigi Palmieri
- Vincenzo CoppolaVincenzo Coppola
- Giuseppe FiermonteGFGiuseppe Fiermonte
Open Access
Abstract
The stable and safe integration of exogenous DNA into the genome is crucial to both genetic engineering and gene therapy. Traditional transgenesis approaches, such as those using retroviral vectors, result in random genomic integration, posing the risk of insertional mutagenesis and transcriptional dysregulation. Safe harbor sites (SHSs), genomic loci that support reliable transgene expression without compromising endogenous gene function, genomic integrity, or cellular physiology, have been identified and characterized across various model organisms. Well-established SHSs such as AAVS1, ROSA26, and CLYBL are routinely utilized for targeted transgene integration in human cells. Recent advances in genome architecture, gene regulation, and genome editing technologies are driving the discovery of novel SHSs for precise and safe genetic modification. This review aims to provide a comprehensive overview of SHSs and their applications that will guide investigators in the choice of SHS, especially when complementary sites are needed for more than one transgene integration. First, it outlines safety and functional criteria that qualify a genomic site as a safe harbor site. It then discusses the two primary strategies for identifying SHSs: i) traditional lentiviral-based random transgenesis, and ii) modern genome-wide in silico screening followed by CRISPR-based validation. This review also provides an updated catalogue of currently known SHSs in the human genome, detailing their characteristics, uses, and limitations. Additionally, it discusses the diverse applications of SHSs in basic research, gene therapy, CAR T cell-based therapy, and biotechnological production systems. Finally, it concludes by highlighting challenges in identifying universally applicable SHSs and outlines future directions for their refinement and validation across biological systems.Keywords
Funding Information
- European Union—NextGenerationEU (CN00000041)
This publication has 197 references indexed in Scilit:
- AAVS1‐targeted, stable expression of ChR2 in human brain organoids for consistent optogenetic controlBioengineering & Translational Medicine, 2024
- Manipulating and studying gene function in human pluripotent stem cell modelsFEBS Letters, 2023
- Determining On‐Target, Off‐Target, and Copy Number Status of Transgenic Events After CRISPR/Cas9 Targeted AAVS1 Safe‐Harbor Modification of iPSCs Using Double‐Control Quantitative Copy Number PCRCurrent Protocols, 2023
- CRISPR/Cas-Mediated Knock-in of Genetically Encoded Fluorescent Biosensors into the AAVS1 Locus of Human-Induced Pluripotent Stem Cells2021
- Long non‐coding RNAs in development and disease: conservation to mechanismsThe Journal of Pathology, 2020
- AAVS1 site‐specific integration of the CAR gene into human primary T cells using a linear closed‐ended AAV‐based DNA vectorThe Journal of Gene Medicine, 2020
- Generation of an Induced Pluripotent Stem Cell Line with the Constitutive EGFP Reporter2020
- Human Genomic Safe Harbors and the Suicide Gene-Based Safeguard System for iPSC-Based Cell TherapyStem Cells Translational Medicine, 2019
- Characterization of a preferred site on human chromosome 19q for integration of adeno‐associated virus DNA by non‐homologous recombination.The EMBO Journal, 1992
- Targeted integration of adeno‐associated virus (AAV) into human chromosome 19.The EMBO Journal, 1991